Global Injectable Drug Delivery Market Analysis By Device Type (Conventional, Self-injection), By Formulation (Novel drugs delivery, Conventional drug delivery, Other Formulations), By End-User (Home Care, Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: May 2024
- Report ID: 16898
- Number of Pages: 208
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
Injectable drug delivery refers to the administration of drugs directly into the body through a needle or syringe, typically intravenously, intramuscularly, or subcutaneously. This method is essential for drugs that are poorly absorbed when taken orally or that are unstable in the digestive tract.
The injectable drug delivery market encompasses technologies, devices, and formulations used in the delivery of drugs via injection. It is driven by the increasing prevalence of chronic diseases, advancements in biologics, and the need for more efficient drug delivery methods.
The market includes various products such as devices like pens, pumps, and syringes, as well as formulations that enhance the stability and efficacy of injectable drugs. The expansion of this market is supported by ongoing research and development activities aimed at improving patient compliance and reducing discomfort associated with injections. This sector is critical in healthcare for its role in treatment effectiveness and patient care improvements.
Injectable drug delivery (IDD) has seen a significant increase in demand due to the rise in chronic diseases like cancer and diabetes. For a quicker course of action, injectables are used for the treatment of a variety of diseases including Wilson’s disease and autoimmune diseases, as well as cystic Fibrosis, hemophilia, and hepatitis C. These drugs are able to be administered to unconscious or comatose patients and are therefore preferred over other forms of drug delivery.
Device Type Analysis
The devices market can further be divided into conventional injection and self-injection devices. self-injection devices held the largest market share. This market’s fastest growing segment is that which includes self-injection devices. These devices allow for the management and control at the primary level of many disorders. The needle-free injections are a breakthrough technology that allows for painless administration. This makes this segment one of the most profitable.
Formulation Analysis
Conventional drug delivery systems can be described as solutions, reconstituted/lyophilized formulas, suspensions, or emulsions. Colloid dispersions can be used to deliver novel drugs. These include liposomes and noisome. They also contain polymeric or mixed micelles. The microparticles have been designed to allow for rapid absorption at the intended location. Colloid dispersions are being used in drug delivery systems in a significant way, as most companies have invested heavily in R&D.
End-User Analysis
According to end-user applications, there is a fragmented market that includes hospitals, home care, Research institutes, and diagnostic laboratories are the other end-user applications. Self-injection devices, such as auto-injectors or pen-injectors, or needle-free injectors, have made it possible for patients to administer IDD at home. The majority of market leaders in this market have created devices that allow the administration of insulin using self-injection devices due to the rise in diabetes cases worldwide.
Key Market Segments
By Device Type
- Conventional
- Self-injection
By Formulation
- Novel drugs delivery
- Conventional drug delivery
- Other Formulations
By End-User
- Home Care
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Other End-Users
Drivers
Rising Prevalence of Chronic Diseases
The increasing incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders is a significant driver for the injectable drug delivery market. These conditions often require long-term, effective management through medications, many of which are most efficacious when delivered via injection. This need supports the growth of advanced injectable drug delivery systems to improve therapeutic outcomes and patient compliance.
For example, the World Health Organization reports that noncommunicable diseases (NCDs) such as cardiovascular diseases, cancers, respiratory diseases, and diabetes account for over 70% of global deaths annually. The rising need for effective chronic disease management through medications, many of which require injection, underpins growth in the injectable drug delivery sector.
Restraints
High Cost of Development
A major restraint in the injectable drug delivery market is the high cost associated with developing new and advanced injection technologies. These costs stem from rigorous research and development processes, clinical testing, and regulatory compliance required to bring a safe and effective product to market. These factors can impede the development pace and the availability of innovative injectable solutions.
The cost of developing new drug delivery systems, particularly injectable ones, is substantial. Research suggests that the average cost to bring a new medical device to market can exceed $30 million, depending on the regulatory pathway and complexity of the device. This financial barrier can slow innovation and limit the entry of new players in the market, particularly in areas requiring cutting-edge technologies.
Opportunities
Biologics and Biosimilars
The growing focus on biologics and biosimilars presents substantial opportunities within the injectable drug delivery market. Biologics require precise, targeted delivery mechanisms, often through injectables, to maintain their efficacy. As patents on existing biologics expire and the demand for biosimilars increases, companies that develop innovative injectable delivery systems are poised to benefit.
Trends
Advancements in Needle-Free Technologies
A notable trend in the injectable drug delivery market is the development of needle-free injection technologies. These advancements aim to reduce the discomfort, needlestick injuries, and contamination risks associated with traditional syringes. The increasing patient preference for less invasive administration methods is driving research and investment in this area, highlighting a shift towards more patient-centric drug delivery solutions.
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Market Key Players
- Baxter International Inc.
- Pfizer Inc.
- Terumo Corporation
- Dickinson and Company
- Becton
- Schott AG
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Other Key Players
Report Scope
Report Features Description Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Device Type (Conventional, Self-injection), By Formulation (Novel drugs delivery, Conventional drug delivery, Other Formulations), By End-User (Home Care, Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Baxter International Inc., Pfizer Inc., Terumo Corporation, Dickinson and Company, Becton, Schott AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Injectable Drug Delivery MarketPublished date: May 2024add_shopping_cartBuy Now get_appDownload Sample - Baxter International Inc.
- Pfizer Inc Company Profile
- Terumo Corporation Company Profile
- Dickinson and Company
- Becton, Dickinson and Company Profile
- Schott AG Company Profile
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |